TP方案时辰化疗对中晚期非小细胞肺癌患者免疫功能的影响  

The Effects of Chrono-Chemotherapy with Paclitaxol puls Cisplatin on Immune Function for Patients with Advanced Non-small Cell Lung Cancer

作　　者：魏成明[1] 

机构地区：[1]四川省自贡市第一人民医院肿瘤科,643000

出　　处：《中国医药指南》2010年第26期23-25,共3页Guide of China Medicine

摘　　要：目的对比观察TP方案的时辰化疗和常规化疗对中晚期非小细胞肺癌患者的免疫功能的影响。方法 68例经病理学或细胞学确诊的初治中晚期非小细胞肺癌患者,随机分为两组,时辰组(CC组):34例,常规组(RC组):34例。结果时辰化疗组:①CD3+、B细胞较化疗前上升,但差异无显著性(P>0.001);②CD4+、CD4+/CD8+、CD8+CD28+较化疗前有显著上升,差异有显著性(P<0.001);③CD8+、CD8+CD28-、NK细胞较化疗前显著下降,差异有显著性(P<0.001)。常规化疗组:①CD3+、CD4+较化疗前上升,但差异无显著性;②CD8+较化疗前略有上升,但差异无显著性;③CD4+/CD8+、CD8+CD28+、CD8+CD28-较化疗前略有下降,但差异无显著性;④NK细胞、B细胞较化疗前有下降,但差异无显著性(P>0.001)。结论 TP方案时辰化疗近期对患者细胞免疫产生影响,提高了患者的细胞免疫功能,对体液免疫无影响。TP方案时辰化疗是一种治疗中晚期非小细胞肺癌的有效方法。Objective To compare the effects on patients＇ immune function of chrono-chemotherapy（paclitaxol puls cisplatin）with routine-chemotherapy for advanced non-small cell lung cancer.Methods Sixty-eight patients with pathological-proved untreated advanced non-small cell lung cancer were randomly divided into the chronological chemotherapy group（group CC,34 cases） and the routine chemotherapy group（group RC,34 cases）.Results In the group CC,the CD3＋ and B cell were no significant difference between pre-and post-chemotherapy（P0.001）,the CD4＋,CD4＋/CD8＋,CD8＋CD28＋were significantly increased and CD8＋,CD8＋CD28-,NK cell were significantly decreased in group CC（P0.001）.While the changes of the measures of immune function were not signif icant in the group RC（P0.001）.Conclusions The short-term immunity effects of chrono-chemotherapy with paclitaxol puls cisplatin is better than that of routine-chemotherapy,it can improve the cellular immune function of patients,and it has no effect on the humoral immunity.So it is recommended to be a better treatment choice of the advanced non-small cell lung cancer.

关 键 词：非小细胞肺癌 时辰化疗 紫杉醇 顺铂 免疫学 

分 类 号：R734.2[医药卫生—肿瘤]